NICE asks Merck to submit Cancer Drugs Fund proposal for immunotherapy drug
The National Institute for Health and Care Excellence (NICE) has asked the pharmaceutical company, Merck, to submit a Cancer Drugs Fund (CDF) proposal for its immunotherapy drug avelumab (Bavencio; Merck).